Clinical Trial Update: DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for DPI 386 nasal gel in prevention of nausea due to motion sickness; study phases 2 and 3 have been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Motion Sickness

Drugs mentioned

• DPI-386 nasal gel

Snippet

Sponsor: Repurposed Therapeutics, Inc. | Conditions: Motion Sickness | Phase 2, Phase 3 | Status: TERMINATED